Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Lipopolysaccharide (LPS) transport system, comprising the inner membrane flippase MsbA and the outer membrane translocon LptD, is essential for the biogenesis of the Gram-negative bacterial outer membrane (UniProt P0ADV1, P31554). MsbA is an ATP-binding cassette (ABC) transporter that translocates Lipid A-core from the cytoplasmic to the periplasmic leaflet of the inner membrane (Zhang et al., Nature 2018). LptD, in complex with LptE, forms a 26-stranded beta-barrel that facilitates the final insertion of LPS into the outer leaflet of the outer membrane (Botos et al., Structure 2016). This pathway is a critical target for novel antibiotics because its disruption leads to the accumulation of toxic LPS intermediates and loss of membrane integrity, resulting in bacterial cell death (Sperandeo et al., J. Bacteriol. 2008). Therapeutic candidates like Murepavadin target LptD, while small molecules such as G907 and G001 have been developed to inhibit MsbA (Martin-Loeches et al., Lancet Infect Dis 2018; Zhang et al., Nature 2018). Despite their potential, the development of these drugs faces challenges including the rapid emergence of resistance mutations and specific safety concerns like the nephrotoxicity observed with certain peptide-based LptD inhibitors.
Inhibition of the lipopolysaccharide (LPS) transport pathway by blocking either the inner membrane flippase MsbA or the outer membrane translocon LptD, preventing the assembly of the bacterial outer membrane.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lipopolysaccharide transport protein D (LptD) and Lipid A export ATP-binding cassette transporter MsbA (MsbA) (LptD/MsbA).